Page last updated: 2024-12-11
interiotherin b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
interiotherin B: isolated from kadsura interior; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
interiotherin B : A lignan with a dibenzocyclooctadiene skeleton attached to a fatty acid ester side chain. It is isolated from Kadsura interior and has been shown to exhibit anti-HIV activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Kadsura | genus | A plant genus of the family SCHISANDRACEAE used in folk medicine in a manner similar to SCHISANDRA. Members contain KADSURENONE and KADSURIN.[MeSH] | Schisandraceae | A plant family of the order AUSTROBAILEYALES, class MAGNOLIOPSIDA.[MeSH] |
Kadsura interior | species | [no description available] | Schisandraceae | A plant family of the order AUSTROBAILEYALES, class MAGNOLIOPSIDA.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 20839677 |
CHEMBL ID | 490161 |
CHEBI ID | 66083 |
MeSH ID | M0270489 |
Synonyms (6)
Synonym |
---|
interiotherin b |
chebi:66083 , |
CHEMBL490161 |
2-butenoic acid, 2-methyl-, (5s,6s,7s,13as)-5,6,7,8-tetrahydro-6-hydroxy-13,14-dimethoxy-6,7-dimethylcycloocta(1,2-f:3,4-f')bis(1,3)benzodioxol-5-yl ester, (2z)- |
Q27134596 |
[(11s,12s,13s)-12-hydroxy-3,22-dimethoxy-12,13-dimethyl-5,7,18,20-tetraoxapentacyclo[13.7.0.02,10.04,8.017,21]docosa-1(22),2,4(8),9,15,17(21)-hexaen-11-yl] (z)-2-methylbut-2-enoate |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
Role | Description |
---|---|
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
anti-HIV agent | An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
Class | Description |
---|---|
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
lignan | Any phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e". |
fatty acid ester | A carboxylic ester in which the carboxylic acid component can be any fatty acid. |
organic heteropentacyclic compound | |
oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (12)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID335886 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 mol ratio relative to TPA | 2002 | Journal of natural products, Sep, Volume: 65, Issue:9 | Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation. |
AID569566 | Antiviral activity against HIV1-3B infected in human C1866 cells assessed as inhibition of virus-induced cytopathic effect | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Compounds from Kadsura angustifolia with anti-HIV activity. |
AID335885 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 mol ratio relative to TPA | 2002 | Journal of natural products, Sep, Volume: 65, Issue:9 | Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation. |
AID569567 | Therapeutic index, ratio of CC50 for human C1866 cells to EC50 for HIV1-3B | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Compounds from Kadsura angustifolia with anti-HIV activity. |
AID354616 | Therapeutic index, ratio of IC50 for mock-infected human H9 cells to EC50 for HIV1 3B | 1996 | Journal of natural products, Nov, Volume: 59, Issue:11 | Two new lignans, interiotherins A and B, as anti-HIV principles from Kadsura interior. |
AID724310 | Inhibition of NF-kappaB (unknown origin) expressed in TNFalpha-stimulated rat HSC-T6 cells assessed as reduction of HSC activation at 50 ug/ml treated 30 mins before TNFalpha stimulation measured after 6 hrs by bioluminescence based luciferase reporter ge | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3 | Anti-liver fibrotic lignans from the fruits of Schisandra arisanensis and Schisandra sphenanthera. |
AID354615 | Cytotoxicity against mock-infected human H9 cells after 4 days | 1996 | Journal of natural products, Nov, Volume: 59, Issue:11 | Two new lignans, interiotherins A and B, as anti-HIV principles from Kadsura interior. |
AID335889 | Cytotoxicity against human Raji cells at 1000 mol ratio by trypan blue staining method | 2002 | Journal of natural products, Sep, Volume: 65, Issue:9 | Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation. |
AID335888 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 mol ratio relative to TPA | 2002 | Journal of natural products, Sep, Volume: 65, Issue:9 | Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation. |
AID569565 | Cytotoxicity against human C1866 cells | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Compounds from Kadsura angustifolia with anti-HIV activity. |
AID354614 | Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA | 1996 | Journal of natural products, Nov, Volume: 59, Issue:11 | Two new lignans, interiotherins A and B, as anti-HIV principles from Kadsura interior. |
AID335887 | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 mol ratio relative to TPA | 2002 | Journal of natural products, Sep, Volume: 65, Issue:9 | Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |